- Conditions
- Cachexia
- Interventions
- GTx-024, Placebo
- Drug
- Lead sponsor
- GTx
- Industry
- Eligibility
- Not listed
- Enrollment
- 159 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 50
- States / cities
- Anchorage, Alaska • Fayetteville, Arkansas • Corona, California + 41 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2329–2352
of 2,738
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hepatocellular Carcinoma
- Interventions
- TheraSphere Y-90 glass microsphere therapy, Durvalumab (Imfinzi) immunotherapy, Tremelimumab immunotherapy
- Device · Drug
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 12
- States / cities
- San Diego, California • San Francisco, California • Washington D.C., District of Columbia + 7 more
- Conditions
- Colorectal Cancer, Gastric Cancer, Gastrointestinal Carcinoid Tumor, Gastrointestinal Stromal Tumor, Ovarian Cancer, Peritoneal Cavity Cancer, Small Intestine Cancer
- Interventions
- carboplatin, cisplatin, floxuridine
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1997
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Hepatocellular Carcinoma (HCC)
- Interventions
- brivanib (active)
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 137 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 19
- States / cities
- Duarte, California • Los Angeles, California • Newark, Delaware + 12 more
- Conditions
- Colorectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma, Colorectal Adenocarcinoma, Colorectal Cancer Metastatic, Colorectal Sarcoma
- Interventions
- No intervention
- Other
- Lead sponsor
- ProgenaBiome
- Other
- Eligibility
- Not listed
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2030
- U.S. locations
- 1
- States / cities
- Ventura, California
- Conditions
- Adenocarcinoma, Carcinoma, Pancreatic Ductal
- Interventions
- Relacorilant, Nab-paclitaxel, Gemcitabine
- Drug
- Lead sponsor
- Corcept Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 20
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Orange, California + 16 more
- Conditions
- Cirrhosis, Hepatocellular Carcinoma
- Interventions
- Vitamin D
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Advanced Solid Tumors
- Interventions
- OSI-906
- Drug
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin), Matching placebo + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 198 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 5
- States / cities
- Wichita, Kansas • Metairie, Louisiana • Brockton, Massachusetts + 2 more
- Conditions
- Colorectal Carcinoma, Lung Adenocarcinoma, Malignant Solid Neoplasm, Pancreatic Carcinoma
- Interventions
- Binimetinib, Palbociclib, Therapeutic Conventional Surgery
- Drug · Procedure
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Hepatocellular Carcinoma
- Interventions
- SGI-110
- Drug
- Lead sponsor
- Astex Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 15
- States / cities
- Duarte, California • Los Angeles, California • Sacramento, California + 11 more
- Conditions
- Metastatic Pancreatic Cancer, Colorectal Cancer, Esophageal Neoplasms, Carcinoma, Non-small-cell Lung
- Interventions
- TAK-931
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 8
- States / cities
- Denver, Colorado • Sarasota, Florida • Minneapolis, Minnesota + 5 more
- Conditions
- Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Kidney Cancer, Leukemia, Liver Cancer, Lung Cancer, Pancreatic Cancer, Tobacco Use Disorder
- Interventions
- smoking cessation intervention, bupropion hydrochloride, gene expression analysis, polymerase chain reaction, counseling intervention, educational intervention, psychosocial assessment and care
- Behavioral · Drug · Genetic + 2 more
- Lead sponsor
- Lisa Sanderson Cox, PhD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 540 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 2
- States / cities
- Kansas City, Kansas • Kansas City, Missouri
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Ramucirumab, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 399 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 8
- States / cities
- Daly City, California • Los Angeles, California • Washington D.C., District of Columbia + 5 more
- Conditions
- Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Peritoneum, Stage IV Colorectal Cancer AJCC v8
- Interventions
- Biopsy, Biospecimen Collection, Computed Tomography, Diagnostic Laparoscopy, Fluorouracil, Magnetic Resonance Imaging, Oxaliplatin, Surgical Procedure
- Procedure · Drug
- Lead sponsor
- Arjun Mittra
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 2
- States / cities
- Columbus, Ohio • Dallas, Texas
- Conditions
- Biliary Tract Cancer
- Interventions
- "Bevacizumab" in combination with "modified FOLFOX6".
- Drug
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Pancreatic Cancer
- Interventions
- Proton Radiation, Capecitabine, Surgical resection
- Radiation · Drug · Procedure
- Lead sponsor
- Proton Collaborative Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2040
- U.S. locations
- 4
- States / cities
- Little Rock, Arkansas • Jacksonville, Florida • Warrenville, Illinois + 1 more
- Conditions
- Metastatic Liver Carcinoma, Stage IV Liver Cancer, Stage IVA Liver Cancer, Stage IVB Liver Cancer
- Interventions
- Angiography, Computed Tomography, Planar Imaging, Radioembolization, Single Photon Emission Computed Tomography, Technetium Tc-99m Albumin Aggregated, Yttrium Y 90 Resin Microspheres
- Procedure · Radiation · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Hepatocellular Carcinoma
- Interventions
- RAD001
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts
- Conditions
- Colorectal Carcinoma, Colorectal Neoplasm, Lynch Syndrome
- Interventions
- Adenovirus 5 CEA/MUC1/Brachyury Vaccine Tri-Ad5, Biopsy Procedure, Biospecimen Collection, Colonoscopy, Nogapendekin Alfa, Placebo Administration, Questionnaire Administration
- Biological · Procedure · Drug + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 186 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Tucson, Arizona • San Francisco, California + 10 more
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- Doxorubicin 20 mg/m2, Doxorubicin 30 mg/m2, Best Standard of Care
- Drug
- Lead sponsor
- Valerio Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 397 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 3
- States / cities
- Canton, Ohio • Hershey, Pennsylvania • Pittsburgh, Pennsylvania
- Conditions
- Liver Cancer, Metastatic Cancer
- Interventions
- Radiofrequency Ablation
- Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2006
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Hypercalcemia, Familial Primary Hyperparathyroidism
- Interventions
- Parathyroid hormone testing, Serum calcium testing
- Procedure
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Liver Metastases, Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma
- Interventions
- Stereotactic body radiosurgery, Stereotactic Body Radiotherapy
- Radiation
- Lead sponsor
- Mercy Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2016
- U.S. locations
- 1
- States / cities
- St Louis, Missouri